|
Classification landmarks | Stage 1 DCM (diastolic dysfunction, hypertrophy) | Stage 2 DCM systolic dysfunction and dilatation | Stage 3 DCM systolic dysfunction, dilatation, associated HTA | Stage 4 DCM including all confounders, also CAD |
|
Correspondence in NYHA classification | Asymptomatic | NYHA II | NYHA II-III | NYHA II–IV |
Metabolic status | Impaired glucose tolerance; metabolic syndrome | Chronic hyperglycemia | Insulin resistance; DM with microangiopathic complications | DM with micro- and macroangiopathic complications |
Echocardiographic features ± coronarography | Increased LV mass, diastolic dysfunction, decreased tissue velocities, normal EF | Increased LV mass and wall thickness, diastolic and systolic dysfunction (EF < 50%) mild cavity dilatation | Diastolic dysfunction and mild systolic dysfunction cavity dilatation | Moderate-severe systolic dysfunction cavity dilatation associated coronary artery disease |
Other DM-related associated comorbidities | | | Microangiopathic complications; HTA | Macroangiopathic complications, including CAD |
Serological markers to be monitored periodically regarding glycemic control, heart failure, and myocardial necrosis | NTproBNP, MMP-3, and osteopontin (according to van der Leeuw et al. 2016) Glc, lipid profile, HbA1C | MMP-3 and osteopontin (according to van der Leeuw et al. 2016) Glc, lipid profile, HbA1C, NTproBNP, BNP | MMP-3 and osteopontin (according to van der Leeuw et al. 2016) Glc, lipid profile, HbA1C, NTproBNP, BNP troponins increased in concurrent ischemia | Glc, lipid profile, HbA1C, NTproBNP, BNP troponins increased in myocardial infarction or severe heart failure |
|